SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma
T cells taken from patients and engineered to recognise the MAGE-A4 protein shrank tumours in about four in ten patients with advanced synovial sarcoma, leading to the first approval of a TCR T-cell therapy for any solid cancer.
Single-arm phase 2 trial of 52 patients (44 with synovial sarcoma, 8 with myxoid/round cell liposarcoma) who were HLA-A*02 positive with MAGE-A4-expressing tumours, previously treated with anthracycline or ifosfamide, treated with a single infusion of afamitresgene autoleucel (afami-cel), autologous T cells expressing an affinity-enhanced MAGE-A4-specific T-cell receptor, after lymphodepleting chemotherapy. Primary endpoint was objective response rate.
The response rate was 37% overall and 39% in synovial sarcoma, with a median duration of response of about 12 months. Cytokine release syndrome occurred in about 70% but was mostly low grade. It led to FDA accelerated approval in 2024 (Tecelra), the first TCR-T and the first engineered cell therapy approved for a solid tumour.
- Objective response 37% overall (19 of 52); 39% in synovial sarcoma and 25% in myxoid/round cell liposarcoma.
- Median duration of response about 12 months; median PFS about 3.8 months and median OS about 15 months in a heavily pretreated population.
- Cytokine release syndrome in about 70% of patients, grade 3 in around 2%; cytopenias were common after lymphodepletion.
- Eligibility required both HLA-A*02 genotype and MAGE-A4 expression, satisfied by roughly a third of screened synovial sarcoma patients.
- Manufacturing success was high but the process took several weeks per patient.
Patients with advanced synovial sarcoma, a rare cancer of young adults with few effective drugs, now have an approved cell therapy that produces responses lasting about a year in a substantial minority, if their tissue type and tumour antigen match. It proves that engineered T cells can work against a solid tumour when a good target is present, which had been elusive. It is not a cure for most, requires specialised centres, and only a minority of patients are eligible.
- Single-arm trial with a response-rate endpoint; no randomised comparison and OS benefit is unproven.
- Restricted to HLA-A*02-positive patients, which excludes many people of non-European ancestry.
- Responses are usually not durable beyond a year; mechanisms of relapse (antigen loss, T-cell exhaustion) are being studied.
- Very high cost and complex logistics for a rare indication.